Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract
Whether patients undergo upfront radical cystectomy (RC) or receive neoadjuvant chemotherapy (NAC) before surgery, timely treatment initiation has become an increasingly important quality indicator in multidisciplinary bladder cancer care. Against this background, notwithstanding the established survival benefit of cisplatin-based NAC, concerns about delaying definitive local treatment continue to limit its adoption in routine clinical practice.
Previous studies have primarily focused on isolated components of the treatment pathway, evaluating either the interval from diagnosis to radical cystectomy or the timing of surgery after neoadjuvant chemotherapy. Our study sought to evaluate time to treatment initiation (TTI) as the interval from diagnosis to the first curative-intent intervention, regardless of whether this consisted of upfront RC or the initiation of NAC. Rather than analyzing surgical and medical treatment delays separately, we integrated both strategies into a single analytical framework, allowing direct comparison of four clinically relevant treatment pathways according to treatment modality and timing.
Using a contemporary national cohort of more than 16,500 patients with non-metastatic MIBC, we observed that the survival benefit associated with NAC was maintained when chemotherapy was initiated within 60 days of diagnosis, whereas this advantage was attenuated when treatment initiation occurred beyond this timeframe. Importantly, these findings should not be interpreted as discouraging the use of NAC. Instead, they reinforce the concept that the benefit of multimodal therapy depends not only on treatment selection but also on the efficiency with which the entire care pathway is delivered. If delivered promptly, NAC maintains a key survival benefit.
The implications extend beyond individual treatment decisions. Delays in MIBC management frequently arise from system-level factors, including referral pathways, multidisciplinary coordination, diagnostic work-up, and access to specialized centers. Consequently, improving outcomes requires organizational strategies aimed at reducing unnecessary delays. Streamlined referral processes, early multidisciplinary evaluation, and optimized diagnostic workflows may all contribute to more timely delivery of curative treatment.
Future studies should focus on identifying modifiable causes of treatment delay and evaluating interventions capable of improving care coordination while preserving the survival benefit of evidence-based multimodal therapy.
Written by: Andrea Piccolini, MD, Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy
Read the Abstract